
As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study
Hepion Pharmaceuticals said Monday morning its drug for nonalcoholic steatohepatitis, or NASH, improved liver function according to an experimental diagnostic and also improved key biomarkers associated with the disease.
In a Phase II study, the New Jersey biotech used an investigational test from collaborator HepQuant, a liver diagnostics company in Denver, to examine liver function and impairment in over 60 patients before and after they received Hepion’s drug candidate rencofilstat. Hepion used the test to measure a number of items including disease severity, which was the primary endpoint of the study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.